Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells

作者: Karianne Risberg , Kathrine Røe Redalen , Linda Sønstevold , Tonje Bjørnetrø , Janne Sølvernes

DOI: 10.1186/S12885-016-2600-Y

关键词:

摘要: Background The use of targeted agents to impel dual inhibition anti-apoptotic mechanisms and mTOR-mediated pro-survival signaling in colorectal carcinoma (CRC) cell lines with KRAS or BRAF mutation has been shown induce apoptosis, a timely result given CRC entities harboring such mutations are need new therapies. Since comprises heterogeneous tumors predominant hypoxic components, we investigated effects an inhibitor Bcl-2 family proteins (ABT-737) combination mTOR (AZD8055)—collectively referred as combo-Rx, lines.

参考文章(32)
Maria Giovanna Francipane, Eric Lagasse, mTOR pathway in colorectal cancer: an update Oncotarget. ,vol. 5, pp. 49- 66 ,(2014) , 10.18632/ONCOTARGET.1548
Sarah Edkins, Sarah O'Meara, Adrian Parker, Claire Stevens, Marcelo Reis, Siân Jones, Chris Greenman, Helen Davies, Gillian Dalgliesh, Simon Forbes, Chris Hunter, Raffaella Smith, Philip Stephens, Peter Goldstraw, Andrew Nicholson, Tsun Leung Chan, Victor E Velculescu, Siu Tsan Yuen, Suet Yi Leung, Michael R Stratton, P Andrew Futreal, Recurrent KRAS Codon 146 Mutations in Human Colorectal Cancer Cancer Biology & Therapy. ,vol. 5, pp. 928- 932 ,(2006) , 10.4161/CBT.5.8.3251
Xiao-Wen Wang, Yan-Jie Zhang, Targeting mTOR network in colorectal cancer therapy. World Journal of Gastroenterology. ,vol. 20, pp. 4178- 4188 ,(2014) , 10.3748/WJG.V20.I15.4178
G Kroemer, L Galluzzi, P Vandenabeele, J Abrams, E S Alnemri, E H Baehrecke, M V Blagosklonny, W S El-Deiry, P Golstein, D R Green, M Hengartner, R A Knight, S Kumar, S A Lipton, W Malorni, G Nuñez, M E Peter, J Tschopp, J Yuan, M Piacentini, B Zhivotovsky, G Melino, Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009 Cell Death & Differentiation. ,vol. 16, pp. 3- 11 ,(2005) , 10.1038/CDD.2008.150
Bradly G. Wouters, Marianne Koritzinsky, Hypoxia signalling through mTOR and the unfolded protein response in cancer Nature Reviews Cancer. ,vol. 8, pp. 851- 864 ,(2008) , 10.1038/NRC2501
Ellen Preuss, Manuela Hugle, Romy Reimann, Marcel Schlecht, Simone Fulda, Pan-Mammalian Target of Rapamycin (mTOR) Inhibitor AZD8055 Primes Rhabdomyosarcoma Cells for ABT-737-induced Apoptosis by Down-regulating Mcl-1 Protein Journal of Biological Chemistry. ,vol. 288, pp. 35287- 35296 ,(2013) , 10.1074/JBC.M113.495986
Robert G. Bristow, Richard P. Hill, Hypoxia, DNA repair and genetic instability Nature Reviews Cancer. ,vol. 8, pp. 180- 192 ,(2008) , 10.1038/NRC2344
M F Huelsemann, M Patz, L Beckmann, K Brinkmann, T Otto, J Fandrey, H J Becker, S Theurich, M von Bergwelt-Baildon, C P Pallasch, R P Zahedi, H Kashkar, H C Reinhardt, M Hallek, C M Wendtner, L P Frenzel, Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia. Leukemia. ,vol. 29, pp. 981- 984 ,(2015) , 10.1038/LEU.2014.320
J. R. Mills, Y. Hippo, F. Robert, S. M. H. Chen, A. Malina, C.-J. Lin, U. Trojahn, H.-G. Wendel, A. Charest, R. T. Bronson, S. C. Kogan, R. Nadon, D. E. Housman, S. W. Lowe, J. Pelletier, mTORC1 promotes survival through translational control of Mcl-1 Proceedings of the National Academy of Sciences of the United States of America. ,vol. 105, pp. 10853- 10858 ,(2008) , 10.1073/PNAS.0804821105